翻訳と辞書 ・ LY-307,452
・ LY-310762
・ LY-320,135
・ LY-334370
・ LY-341,495
・ LY-344,545
・ LY-367,265
・ LY-379,268
・ LY-404,039
・ LY-404,187
・ LY-487,379
・ LY-503,430
・ LY-60 / FD-60 / PL10
・ Ly-Cilph
・ Ly-Fontaine
・ LY2181308
・ LY294002
・ LY6
・ LY6E
・ LY6G6E
・ LY75
・ LY9
・ Lya
・ Lya (given name)
・ Lya Barrioz
・ Lya De Putti
・ Lya Imber
・ Lya Luft
・ Lya Lys
・ Lya Mara
|
|
LY2181308
LY2181308 is an antisense oligonucleotide that complementarily binds to survivin mRNA and inhibits its expression in tumor tissue.
It being investigated for a number of different cancers.〔http://clinicaltrials.gov/ct2/results?term=LY2181308〕
It is targeted at survivin which prevents cells dying.〔http://www.isispharm.com/Pipeline/Therapeutic-Areas/Cancer.htm#LY2181308〕
==Clinical trials==
It has completed a phase II trial for acute myeloid leukemia.〔(A phase II Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia )〕
A phase II trial for non-small cell lung cancer has started.〔(A Phase II Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer )〕
A phase II trial for hormone-refractory prostate cancer will run until early 2012.〔(A Phase II Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer )〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「LY2181308」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|